Sign Out
Adalimumab has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis patients taking adalimumab as monotherapy and those taking concomitant methotrexate. Antibody formation was lower when adalimumab was given together with methotrexate in comparison with use as monotherapy. Administration of adalimumab without methotrexate resulted in increased formation of antibodies, increased clearance and reduced efficacy of adalimumab (see Pharmacology: Pharmacodynamics under Actions).
The combination of adalimumab and anakinra is not recommended (see "Concurrent administration of biologic DMARDs or TNF-antagonists" under Precautions).
The combination of adalimumab and abatacept is not recommended (see "Concurrent administration of biologic DMARDs or TNF-antagonists" under Precautions).
Continue with Google